News

There are times when physicians should be critical of scans.

In a study, investigators demonstrated the safety and therapeutic potential of clinically compliant iPSC-derived photoreceptor precursors as a cell replacement source for future clinical trials.

Demographics show high demand for solutions beyond eyeglasses.

Oyster Point Pharma, Inc. announced Monday that the U.S. FDA has granted approval of its TYRVAYA (varenicline solution) nasal spray 0.03 mg for the treatment of dry eye disease (DED), making it the first — and only — nasal spray approved for DED treatment in the U.S

A team of Israeli investigators sought to characterize breakthrough cases by evaluating health care workers with COVID-19 symptoms or who had been exposed to the virus.

Longtime clinician, researcher and head of the Ophthalmology Department at UCSF will succeed David W. Parke II, MD, at Academy helm.

Techniques, technologies minimize complications and guide counseling, care.

New data finds that preoperative ptosis occurs commonly and more often in patients with reactive blepharospasm or enophthalmos.

The FDA will decide whether to authorize the boosters based off the advisory panel's recommendations.

Ocular herpes infection is a leading cause of infectious blindness and can lead to lethal brain infections. Using genetically modified mice models, investigators uncovered the importance of mTORC2 in activation of innate- and virus-adaptive immunity during ocular HSV-1 infection.

Investigators find that long-term ocular complications require further observation.

To mark World Sight Day, Nanodropper Inc. has developed a pay-it-forward Nanodropper Adaptor program, allowing anyone to donate devices to a pool for distribution to patients in need.

As the world comes together to shine a global spotlight on blindness and vision impairment on World Sight Day, several global organizations and companies are stepping up to increase awareness of eye health, including the importance of regular examinations by an ophthalmologist or optometrist.

Papilledema with back pain suggests spine lesion.

Oxurion NV announced Wednesday the first patient to be dosed in the INTEGRAL phase 2 clinical study evaluating THR-687 as a treatment for patients with DME.

Results from Aurion Biotech's IOTA trial reveals that a corneal endothelial cell therapy showed improvements in visual acuity and central corneal thickness, according to a team of Japanese investigators.

Cynthia Matossian, MD, FACS, ABES, takes a look at the recent, sudden change in low-payment reimbursement by Medicare Administrative Contractors for LipFlow and MGD procedure codes.

A simple solution that involves use of air filtration devices may help reduce the risk of hospital-acquired SARS-CoV-2 infections.

Aerie Pharmaceuticals announced Tuesday positive topline results for the phase 3 trial evaluating netarsudil 0.02% versus ripasudil 0.4% for the treatment of open-angle glaucoma and elevated IOP.

Changes in health care industry can affect the way ophthalmologists plan their finance.

The FDA approved Ocular Therapeutix Inc.’s Supplemental New Drug Application (sNDA) that further extends Dextenza’s (dexamethasone ophthalmic insert) 0.4 mg indications, the company announced Monday.

Merck and Ridgeback Biotherapeutics are seeking emergency use authorization for molnupiravir, an oral experimental antiviral treatment for mild-to-moderate COVID-19 in adults at risk for virus progression or hospitalization.

David Boyer, MD, reports on the use of pegcetacoplan to treat geographic atrophy when administered monthly or every-other-month regimens in the phase 3 DERBY and OAKS studies.

Arshad Khanani, MD, MA, reports primary study findings from the phase 3 study on the Port Delivery System with ranibizumab.

Investigators in the United Kingdom found that concomitant vaccination of flu and COVID-19 raised no safety concerns and preserved the immune response to both vaccines.

Changes are resulting in better outcomes for patients with glaucoma.

Richard B. Rosen, MD, DSc(Hon), reports on the capabilities of using clinical OCT for imaging and measuring macular surface macrophage cells during the 2021 ASRS annual meeting.

Sunir Garg, MD, reports on the risk of presumed infectious endophthalmitis following administration of anti-VEFG injections in correlation with universal masking.